-- AstraZeneca has shelved a plan to build a vaccine manufacturing plant in Speke, near Liverpool, valued at 450 million pounds ($558.7 million), after months of talks with British government officials about state investment, the Financial Times reports, citing a company statement and unnamed sources.
-- Keir Starmer's Labour government last year sought to reduce the amount of state support to 40 million pounds from 90 million pounds, but U.K. officials last month put forward an offer significantly higher than 40 million pounds, the FT says, citing unnamed sources.
-- The final offer was one of the factors influencing its decision to ditch the plan, AstraZeneca said, according to the FT.
Full story: https://tinyurl.com/5yxveb6e
Write to Cristina Gallardo at cristina.gallardo@wsj.com
(END) Dow Jones Newswires
January 31, 2025 11:07 ET (16:07 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.